| Name | Sucralfate |
| Description | Sucralfate (Sucrose octasulfate–aluminum complex) is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers. |
| Cell Research | Sucralfate is dissolved or suspended in culture medium containing 20% FBS. Cells are incubated with the agent at 37°C under 5% CO2, in air for 0.5-4 h. In some cases, cells are treated with 10-5mol/L indomethacin for 4h before the addition of the agent to determine whether or not intracellular prostaglandins are involved in the protective mechanisms of sucralfate. (Only for Reference) |
| In vitro | Sucralfate may inhibit intestinal epithelial motility by sterically interfering with adhesion to collagen I[3]. It protects RGMl cells from acid- and pepsin-induced damage[4]. |
| In vivo | The protective effects of sucralfate against ARC(acute radiation colitis) may be partially due to the supression of radiation-induced apoptosis by way of p53 in the colon and the protection of the colonic epithelial stem cell region[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20.87 mg/mL (10 mM)
H2O : 0.4 mg/mL (0.20 mM), when pH is adjusted to 2 with HCl. Sonication is recommended.
|
| Keywords | Sucrose octasulfate-aluminum complex | Sucralfate | ProstaglandinReceptor | Prostaglandin Receptor | PGF | Pepsin | Inhibitor | inhibit | Fibrinogen chain | FGF2 | Bacterial |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | Urethane | Sulfamethoxazole sodium | Doxycycline | Ferulic Acid | Isoeugenol | Dimethyl sulfoxide |
| Related Compound Libraries | Membrane Protein-targeted Compound Library | Anti-COVID-19 Compound Library |
United States
